---
layout: post
title: "Labeling for Biosimilar and Interchangeable Biosimilar Products; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:56:51 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-20141
original_published: 2023-09-18 00:00:00 +0000
significance: 8.00
---

# Labeling for Biosimilar and Interchangeable Biosimilar Products; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** September 18, 2023 00:00 UTC
**Document Number:** 2023-20141

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Labeling for Biosimilar and Interchangeable Biosimilar Products." This draft guidance is intended to help applicants develop draft labeling for proposed biosimilar and interchangeable biosimilar products. The recommendations for biosimilar and interchangeable biosimilar product labeling in this draft guidance pertain only to the prescribing information, except for certain recommendations pertaining to FDA-approved patient labeling (e.g., Patient Information, Medication Guide, Instructions for Use). This draft guidance provides an overview of FDA's recommendations for labeling for biosimilar and interchangeable biosimilar products. When finalized, this draft guidance will revise and replace the guidance for industry entitled "Labeling for Biosimilar Products."

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/09/18/2023-20141/labeling-for-biosimilar-and-interchangeable-biosimilar-products-draft-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2023-20141

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
